Brolucizumab Biosimilar - Research Grade

Human

VEGFA

>1mg/ml

Human scFv-kappa-heavy

CHO Cells

Bevacizumab Biosimilar - Research Grade (ICH4003), Aflibercept Biosimilar - Research Grade (ICH4015), Ranibizumab Biosimilar - Research Grade (ICH4031), Suvemcitug Biosimilar - Research Grade (ICH5889), Tarcocimab Biosimilar - Research Grade (ICH5901), Varisacumab Biosimilar - Research Grade (ICH5969)

https://www.imgt.org/mAb-DB/

ICH3002

P15692

Blue ice

This is an unconjugated, non-therapeutic recombinant research-grade analog of brolucizumab, a humanized single-chain antibody fragment (scFv) directed against human vascular endothelial growth factor A (VEGF-A). It reproduces the antigen-binding specificity of the originator molecule and is supplied for research use only; it is not the clinical product and is not intended for human or veterinary use. Because it is delivered as a small scFv format built around the VEGF-A target, it is a convenient reagent for anti-VEGF binding and neutralisation experiments, as a positive control or benchmark alongside other anti-VEGF-A binders, and for antibody-format and assay development work. The molecule is offered at low endotoxin levels (research grade <1 EU/mg; ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities to support in-vitro assays, comparability panels, and preclinical model work. Use it where a well-characterised, cost-effective VEGF-A-binding analog is needed rather than a formulated therapeutic. Guidance provided here is for ichorbio internal review. VEGF-A (gene VEGFA; UniProt P15692) is the prototypical member of the VEGF/PDGF growth-factor family and the master regulator of angiogenesis and vascular permeability. It is produced as multiple isoforms by alternative splicing (e.g. VEGF121, VEGF165, VEGF189), which differ in heparin- and neuropilin-binding and in diffusibility. VEGF-A signals as a disulfide-linked homodimer chiefly through the receptor tyrosine kinases VEGFR-1 (FLT1) and VEGFR-2 (KDR), with VEGFR-2 driving endothelial proliferation, migration, survival and permeability. Its expression is strongly induced by hypoxia via HIF-1alpha. Pathological VEGF-A activity underlies tumour neovascularisation and ocular neovascular disease, making VEGF-A neutralisation a central therapeutic and research strategy. Anti-VEGF-A binders act by sequestering the ligand and preventing receptor engagement.

ESBA-1008, ESBA1008, RTH258, vascular endothelial growth factor A, VEGF-A, VEGF

Detects human VEGFA

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Brolucizumab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Brolucizumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Brolucizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Brolucizumab that binds VEGFA.